# Pitfalls of minimally invasive pancreatoduodenectomy

**Patrick W. Underwood, Michael H. Gerber, Steven J. Hughes**

Department of Surgery, University of Florida College of Medicine, Gainesville, FL, USA

*Correspondence to:* Steven J. Hughes, MD, FACS. Cracchiolo Family Professor and Chief, Division of General Surgery, University of Florida, College of Medicine, 1600 SW Archer Rd, Rm 6165, PO Box 100109, Gainesville, FL 32610-0109, USA. Email: Steven.hughes@surgery.ufl.edu.

**Abstract:** Minimally invasive approaches to abdominal surgical procedures have provided superior outcomes when compared to the open approach and thus have become the standard of care. However, minimally invasive pancreatoduodenectomy (MIPD) presents unique difficulties for both laparoscopic and robotic platforms and remains controversial. Ongoing concerns continue about the minimally invasive approach creating meaningful benefit when system-wide data may suggest MIPD results in increased morbidity and mortality during the learning curve. This treatise explores the current state of MIPD, reviewing the volume and quality of data that supports benefit while contrasting the benefits to the unique challenges associated with MIPD that may lead to unacceptable rates of complications and death. We conclude that in a handful of centers, MIPD confers an iterative but not transformative benefit. Significant barriers to the wide-spread acceptance of MIPD are apparent and persist, including: lack of high level data confirming clinical benefit, well defined patient selection criteria, formal education programs that address challenges of the learning curve, and ultimately value.

**Keywords:** Laparoscopic; robotic; pancreaticoduodenectomy; Whipple; pancreas; pancreatic cancer

## Introduction

In his 1994 manuscript reporting the first laparoscopic pancreatoduodenectomy (LPD), Gagner stated "*the benefit of a laparoscopic approach to surgery of this magnitude may not be as apparent as that of a less-complex laparoscopic procedure*" (1). Over 20 years later, his statement remains remarkably accurate. Minimally invasive approaches to surgery have become the standard of care for most surgical procedures in the abdomen, but minimally invasive pancreatoduodenectomy (MIPD) has largely remained confined to select centers.

Nationwide databases imply that MIPD is being explored by an increasing number of centers (2). The associated outcomes during this "exploratory phase" appear unacceptable as compared to those of the well-established, open surgical approach (3,4). This raises the questions: is MIPD feasible, does it provide benefit, what are the selection criteria, where does one train to perform these procedures, and what credentials should the surgeon and

hospital require? The present literature provides single surgeon or institution outcomes, but high-level data to help answer these questions remains scarce (5-12). Here, we present the challenges/pitfalls of MIPD in the context of the present data addressing the notion that MIPD confers benefit to the patient.

## In select centers, MIPD confers superior patient outcomes

The majority of the available comparative data regarding the potential benefit of MIPD is of poor quality, arising from single surgeon or single center experiences. Typically, these comparative studies have evaluated outcomes between surgeons performing MIPD with surgeons who do not. Large-scale analysis of national databases also has inherent flaws. The surgical volume of centers performing pancreatoduodenectomy, whether open or minimally invasive, varies greatly. The comparison of high volume surgeons or centers doing open pancreatoduodenectomy

**Table 1** Outcomes of minimally invasive pancreatoduodenectomy

| Endpoint | Outcome | Relative difference | Reference(s) |
|---|---|---|---|
| Intraoperative outcomes | | | |
| Operative time | Increased | Increased by 0–207 minutes | (6,7,10,13-21) |
| Estimated blood loss | Decreased | Reduced by 151–1,460 mL | (6,7,10,18,21) |
| Oncologic outcomes | | | |
| Tumor size | Smaller | 0.6 cm smaller | (6,15) |
| Lymph nodes resected | No difference | – | (6,10,13,15,17,18,21,22) |
| R0 resection | No difference/increased rate | – | (6,13,15,21,22) |
| Received adjuvant chemotherapy within 90 days | Increased | 7% increase | (23) |
| Post-operative outcomes | | | |
| Delayed gastric emptying | No difference | – | (13,15-17,20,21,24) |
| Pancreatic fistula | No difference | – | (13,15-17,20,21,24) |
| Wound infection | Reduced | 6–50% less | (6,10,17,20,25) |
| Length of stay | Less | 2–4.4 days less | (4,6,7,10,13,14,16,17,20-22) |
| Mortality | No difference | – | (10,13,15-18,20-22) |

(OPD) compared to low volume MIPD, and vice versa, is not a fair comparison. A multi-center, randomized control trial comparing MIPD to OPD with high volume surgeons would be necessary but logistically difficult. Only two, single center, randomized control trials have been published (10,13). Thus, high-level data supporting the benefit MIPD is lacking. *Table 1* catalogs clinical outcomes from multiple studies comparing MIPD with OPD.

*Intraoperative outcomes*

As expected, multiple studies have shown that MIPD is associated with longer operative times. The difference in mean operative times varies from 0–207 minutes between studies (6,7,10,14-19). The primary intraoperative benefit is decreased estimated blood loss (EBL). Decrease in EBL ranges from 151 to 1,460 mL, but is consistently lower across studies (6,7,10,13-19). However, the evidence that this has could lead to a consistent reduction in rates of transfusion of packed red blood cells is inconsistent. In a recent evaluation of NSQIP data comparing MIPD to OPD, blood loss requiring transfusion within 72 hours after operation was reduced from 14.4% to 7.9% (20). On the other hand, Poves *et al.* did not demonstrate significant differences in transfusion requirement in a recent single center randomized trial.

*Early post-operative outcomes*

Analysis of post-operative outcomes identifies some benefits of MIPD. Patients appear to benefit from shorter ICU and total length of stay (4,6,7,10,13,14,16,17). Total length of stay in MIPD has been shown to be decreased between 2–4 days compared to OPD. The rate of surgical site infection (SSI) appears to be decreased in MIPD. Multiple studies have demonstrated a decrease in SSI ranging from 6% to 50% (6,10,17,25). Unfortunately, none of these studies have quantified the clinical impact of these SSIs.

Post-operative pancreatic fistula (POPF) and delayed gastric emptying (DGE) represent the most clinically important complications after PD, impacting mortality, length of stay, and quality of life. A reduction in either of these complications would confer significant benefit. Unfortunately, MIPD is not associated with a decrease in either of these complications (13,15-17,24). Not surprising, overall morbidity is not different between MIPD and OPD (10,15-18).

*Oncologic outcomes*

Two, single institution studies have demonstrated that long-term oncologic outcomes between MIPD and OPD are

similar (6,15). These studies noted smaller tumor size in MIPD specimens and an associated superior R0 resection rate. Analysis of patients in the National Cancer Database, demonstrated no difference in overall survival in patients undergoing LPD *vs.* OPD (22). A meta-analysis further confirmed this finding (21). Amongst five studies that evaluated surrogates of oncologic outcome, two studies found an increase in total number of lymph nodes harvested in the MIPD arm (6,10,15,17,18). Adjuvant chemotherapy has been shown to improve survival in patients with pancreatic cancer (26). Croome *et al.* were able to show a significant decrease in patients receiving delayed adjuvant chemotherapy or no chemotherapy at all after LPD (23), but this is conflicted by an analysis of the national cancer database (22). Overall, there is no strong evidence that MIPD provides superior oncologic outcomes.

### Laparoscopic vs. robotic pancreatoduodenectomy

Centers performing MIPD tend to do LPD or RPD, but not both, so comparison is challenging. A recent analysis of NSQIP data by Nassour *et al.* compared 235 LPD to 192 RPD (27). Patient selection appears different with RPD patients less likely to have undergone neoadjuvant chemotherapy or need vascular or multi-visceral resection. RPD were less like to be converted to open (11.4% *vs.* 26.0%), but other outcomes such as operative time, reoperation rate, length of stay, 30-day mortality, and major complication rates were similar. RPD were more likely to have superficial SSI (9.3% *vs.* 3.8%). Analysis of oncologic outcomes provided by the National Cancer Database, including overall survival, was also similar (28). Overall, major outcomes are likely similar between the two groups but further studies are warranted.

The often mentioned difference between RPD and LPD include availability, articulation, haptic feedback, 3-dimensional imaging, image stabilization, and cost. These differences drive surgeon preference for one platform over the other, but the general consensus at this time is that the robotic platform is less demanding on surgeon skill but does come at the expense of requiring additional training.

## Pitfalls & challenges of MIPD

### Clinical volume meets the learning curve

Intraoperative exposure, such as the Kocher maneuver, and reconstruction including the pancreatojejunostomy

vary significantly between open and minimally invasive approaches. *Figure 1* depicts a few of the many technical challenges associated with MIPD. There is a small volume of literature that addresses early experience in MIPD, and it suggests that at a high-volume pancreatic surgery center, MIPD can be safely implemented (12,29). But, is this experience reproducible? MIPD outcomes improve progressively with case volume. Proficiency seems to be attained after about 40–80 cases (30-32). In reality, pancreatic surgery is uncommon and few hospitals can provide such a volume of pancreatic disease burden to realistically facilitate programmatic adoption of MIPD. Only 5% of the 634 hospitals performing PD in the National Cancer Database perform greater than twenty cases per year (33). Not only are the high volume centers sparse throughout the country, many of the high volume centers would still require surgeons to spend multiple years attaining proficiency.

PD surgical volume matters. It is well described that high volumes centers have markedly improved outcomes after OPD (34-37). The same applies for MIPD but is not followed in practice. Adam *et al.* evaluated 865 patients who had undergone MIPD from the Healthcare Cost and Utilization Project National Inpatient Sample from 2000 to 2012. The median number of cases per hospital was six. In support of the notion that iterative practice impacts results, post-operative complication rates decreased as hospital volume increased, plateauing at 22 cases per year (3). In an evaluation of data obtained from the National Cancer Database, Sharpe *et al.* found increased 30-day mortality at centers doing less than ten MIPD per year (4). Torphy *et al.* report a similar decrease in 90-day mortality at centers performing more than 6 MIPD per year (38). A review of the National Cancer Database demonstrated that only half of the 246 hospitals performing MIPD over a two year period had performed more than one (2). These studies hint that many centers are attempting MIPD but are still in their infancy in regards to the learning curve.

This volume-equals-quality reality has driven regionalization of PD, and this may present the opportunity for high-volume centers to safely and effectively adopt MIPD. Training programs in MIPD are presently lagging behind interest, but new programs to precept and proctor MIPD are being developed. de Rooij *et al.* implemented a training program to include "technique description, video training, and proctoring" to help ensure safe practice and acceptable outcomes of LPD (39). Hogg *et al.* offer a video-based, coaching curriculum to better prepare surgeons for

**Figure 1** Laparoscopic pancreatoduodenectomy presents unique challenges including: (A) Kocher exposure of D3/D4; (B) uncinate dissection off of the superior mesenteric artery and vein; (C) identification and preservation of anatomic variations such as an aberrant course of the right hepatic artery; (D) difficult reconstruction. IVC, inferior vena cava; LOT, Ligament of Treitz; CBD, common bile duct; GDA, gastroduodenal artery; PV, portal vein; SMA, superior mesenteric artery; RHA, right hepatic artery.

minimally invasive pancreatic resections within the context of a competitive, high-volume surgical oncology residency program (33). Programs such as these may finally offer opportunities to train new surgeons through the learning curve in MIPD.

The optimal patient for initial attempts at MIPD seeks unaffected dissection planes (i.e., neuroendocrine neoplasm or duodenal gastrointestinal stromal tumor), but also then presents the worst possible candidate with respect to the risk for POPF (40,41). In fact, patient selection for MIPD varies widely by surgeon and center (*Table 2*). These varied inclusion and exclusion criteria make comparisons of outcomes across centers difficult. The most common indications for MIPD appear to be periampullary cancers and the most common exclusion appears to be patients with borderline resectable disease. Coupled with the concept of operative volume above, the notion that a small pancreatic cancer leading to a "double-duct-sign" with pristine tissue planes will be available in abundance for a novice MIPD

surgeon to gain experience upon is naïve.

## Considerations unique to MIPD

### Post-pancreatectomy hemorrhage

Based upon our (SJH) experience, post-pancreatectomy hemorrhage following MIPD is noteworthy. Multiples series, including our experience, have not found significant differences between the two approaches in this regard (6,10,15), but the authors caution surgeons early in their experience with MIPD not to rely upon staplers and energy devices in the management of vessels that would be controlled in an open procedure with ligatures. Chopinet *et al.* described their experience with 65 LPD to 65 matched OPD and noted an increased rate of post-pancreatectomy hemorrhage as a particular concern (19). Of the patients who underwent LPD, 21% experienced post-pancreatectomy hemorrhage compared to 14% after OPD. Fortunately, this difference in post-pancreatectomy

**Table 2** Inclusion and exclusion criteria of multiple experiences with minimally invasive pancreatoduodenectomy

| Year | Eligible patients | Exclusion criteria | Procedure | Reference |
|---|---|---|---|---|
| 2010 | Benign and malignant disease | Possible venous resection | Laparoscopic PD | (7) |
| 2012 | Resectable pancreatic tumors | Medical comorbidities, high risk for non-R0 resection | Robotic PD | (11) |
| 2012 | Patient preference for laparoscopic PD | Major PV resection, "hostile abdomen" | Laparoscopic *vs.* open PD | (14) |
| 2013 | Small periampullary tumors, benign lesion, low grade malignancy | No comorbidities | Laparoscopic PD assisted by mini-laparotomy | (8) |
| 2014 | Patients undergoing PD with vascular resection | – | Laparoscopic *vs.* open PD | (23) |
| 2015 | Benign and malignant disease | – | Laparoscopic PD | (12) |
| 2016 | Periampullary cancers | Borderline resectable disease, morbid obesity, adhesive disease | Laparoscopic *vs.* open PD | (6) |
| 2016 | Periampullary tumors | SMV/PV or SMA involvement, adjacent organ invasion | Robotic *vs.* open PD | (18) |
| 2017 | Periampullary cancers | Vascular invasion, Neoadjuvant chemotherapy | Laparoscopic *vs.* open PD | (10) |
| 2018 | Periampullary cancers | Vascular invasion, neoadjuvant chemotherapy | Laparoscopic *vs.* open PD | (19) |

PD, pancreaticoduodenectomy; SMV, superior mesenteric vein; PV, portal vein; SMA, superior mesenteric artery.

hemorrhage has not been supported by multiple other studies (6,10,13,15).

### *Emergent conversion—the second learning curve*

Conversion to an open procedure to achieve the surgical goal safely or effectively is germane to minimally invasive surgery. Conversion rates from MIPD to OPD are reported to be in range of 6–16% (6,11,12,14-16), although Chapman *et al.* report a conversion rate of 30% in patients over the age of 75 in a review of the National Cancer Database (42). Itemized reasons for conversion include: underestimation of disease burden, failure to progress intra-operatively, vascular involvement, and uncontrollable hemorrhage.

Uncontrollable hemorrhage deserves further discussion. The natural evolution of applying minimally invasive approaches to established procedures is to expand the pool of candidates by iteratively accepting increasing levels of technical challenge and risk. For example, a select, few high-volume centers now routinely perform MIPD with portal vein resection and reconstruction (43,44)—these cases were not in the initial inclusion criteria for MIPD at these centers. During this expansion of the capabilities of MIPD

by an individual surgeon or center, emergent conversions for uncontrollable hemorrhage occur. In our series, this occurred roughly between the 75th and 150th case, and the mortality rate for these eight patients was 25% (unpublished data). This concept became a significant point of discussion at the International Hepato-Pancreato-Biliary Association Meeting in Sao Paolo, Brazil in 2017 (45), but the risks and challenges of this second learning curve remain poorly understood or defined.

### MIPD does not incur increased overall cost

In fee-for-service health care systems, there is a hypothetical market advantage to offering minimally invasive surgical options to patients. The marketing of robotic or laparoscopic surgery appeals to patients and has the potential to increase operative volume, but presently, there is no other financial incentive driving surgeon interest in MIPD.

Multiple cost analyses of LPD have found that the laparoscopic approach is associated with increased operative cost (46-48). This expense may be underestimated during the learning curve given longer operative times and the

inclusion of multiple attending surgeons. Further, there is no separate CPT code for MIDP to offset this cost. Yet, despite this difference in operating room cost, the total cost of index hospitalization tends to be equivalent to OPD (46-48). This may be due to offsetting the increased operating room cost by a shorter intensive care unit stay and total length of hospital stay. Two studies have demonstrated a decreased rate of discharge to continued care facilities which may help decrease total episode of care cost, but complete data to support this notion are not available (25,46).

## Conclusions

Multiple pitfalls have prevented MIPD from gaining traction since it was first described in 1994. A handful of high-volume centers routinely offer MIPD to the majority of PD patients and have produced data that suggests subtle benefit over OPD. A lack of convincing, high-quality data showing transformative benefit in clinical outcomes or cost as seen with adaptation of other surgical procedures has tempered growth. Further, the need for a large volume of a relatively uncommon operation coupled with a significant learning curve will confine MIPD to select centers. These forces will continue to limit adoption and expansion of MIPD and enthusiasm for creating formal training programs in MIPD.

## Acknowledgements

## Footnote

*Conflicts of Interest:* The authors have no conflicts of interest to declare.

## References

1. Gagner M, Pomp A. Laparoscopic pylorus-preserving pancreatoduodenectomy. Surg Endosc 1994;8:408-10.
2. Adam MA, Choudhury K, Dinan MA, et al. Minimally Invasive Versus Open Pancreaticoduodenectomy for Cancer: Practice Patterns and Short-term Outcomes Among 7061 Patients. Ann Surg 2015;262:372-7.
3. Adam MA, Thomas S, Youngwirth L, et al. Defining a Hospital Volume Threshold for Minimally Invasive Pancreaticoduodenectomy in the United States. JAMA Surg 2017;152:336-42.
4. Sharpe SM, Talamonti MS, Wang CE, et al. Early National Experience with Laparoscopic Pancreaticoduodenectomy for Ductal Adenocarcinoma: A Comparison of Laparoscopic Pancreaticoduodenectomy and Open Pancreaticoduodenectomy from the National Cancer Data Base. J Am Coll Surg 2015;221:175-84.
5. Croome KP, Farnell MB, Que FG, et al. Pancreaticoduodenectomy with major vascular resection: a comparison of laparoscopic versus open approaches. J Gastrointest Surg 2015;19:189-94; discussion 194.
6. Delitto D, Luckhurst CM, Black BS, et al. Oncologic and Perioperative Outcomes Following Selective Application of Laparoscopic Pancreaticoduodenectomy for Periampullary Malignancies. J Gastrointest Surg 2016;20:1343-9.
7. Kendrick ML, Cusati D. Total laparoscopic pancreaticoduodenectomy: feasibility and outcome in an early experience. Arch Surg 2010;145:19-23.
8. Kim SC, Song KB, Jung YS, et al. Short-term clinical outcomes for 100 consecutive cases of laparoscopic pylorus-preserving pancreatoduodenectomy: improvement with surgical experience. Surg Endosc 2013;27:95-103.
9. Lee JS, Han JH, Na GH, et al. Laparoscopic pancreaticoduodenectomy assisted by mini-laparotomy. Surg Laparosc Endosc Percutan Tech 2013;23:e98-102.
10. Palanivelu C, Senthilnathan P, Sabnis SC, et al. Randomized clinical trial of laparoscopic versus open pancreatoduodenectomy for periampullary tumours. Br J Surg 2017;104:1443-50.
11. Zeh HJ, Zureikat AH, Secrest A, et al. Outcomes after robot-assisted pancreaticoduodenectomy for periampullary lesions. Ann Surg Oncol 2012;19:864-70.
12. Paniccia A, Schulick RD, Edil BH. Total Laparoscopic Pancreaticoduodenectomy: A Single-Institutional Experience. Ann Surg Oncol 2015;22:4380-1.
13. Poves I, Burdio F, Morato O, et al. Comparison of Perioperative Outcomes Between Laparoscopic and Open Approach for Pancreatoduodenectomy: The PADULAP Randomized Controlled Trial. Ann Surg 2018;268:731-9.
14. Asbun HJ, Stauffer JA. Laparoscopic vs open pancreaticoduodenectomy: overall outcomes and severity of complications using the Accordion Severity Grading System. J Am Coll Surg 2012;215:810-9.
15. Correa-Gallego C, Dinkelspiel HE, Sulimanoff I, et al. Minimally-invasive vs open pancreaticoduodenectomy: systematic review and meta-analysis. J Am Coll Surg 2014;218:129-39.
16. de Rooij T, Lu MZ, Steen MW, et al. Minimally Invasive Versus Open Pancreatoduodenectomy: Systematic Review

and Meta-analysis of Comparative Cohort and Registry Studies. Ann Surg 2016;264:257-67.

17. Qin H, Qiu J, Zhao Y, et al. Does minimally-invasive pancreaticoduodenectomy have advantages over its open method? A meta-analysis of retrospective studies. PLoS One 2014;9:e104274.

18. Zureikat AH, Postlewait LM, Liu Y, et al. A Multi-institutional Comparison of Perioperative Outcomes of Robotic and Open Pancreaticoduodenectomy. Ann Surg 2016;264:640-9.

19. Chopinet S, Fuks D, Rinaudo M, et al. Postoperative Bleeding After Laparoscopic Pancreaticoduodenectomy: the Achilles' Heel? World J Surg 2018;42:1138-46.

20. Nassour I, Wang SC, Christie A, et al. Minimally Invasive Versus Open Pancreaticoduodenectomy: A Propensity-matched Study From a National Cohort of Patients. Ann Surg 2018;268:151-7.

21. Chen K, Pan Y, Liu XL, et al. Minimally invasive pancreaticoduodenectomy for periampullary disease: a comprehensive review of literature and meta-analysis of outcomes compared with open surgery. BMC Gastroenterol 2017;17:120.

22. Kantor O, Talamonti MS, Sharpe S, et al. Laparoscopic pancreaticoduodenectomy for adenocarcinoma provides short-term oncologic outcomes and long-term overall survival rates similar to those for open pancreaticoduodenectomy. Am J Surg 2017;213:512-5.

23. Croome KP, Farnell MB, Que FG, et al. Total laparoscopic pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: oncologic advantages over open approaches? Ann Surg 2014;260:633-8; discussion 638-40.

24. McMillan MT, Zureikat AH, Hogg ME, et al. A Propensity Score-Matched Analysis of Robotic vs Open Pancreatoduodenectomy on Incidence of Pancreatic Fistula. JAMA Surg 2017;152:327-35.

25. Zimmerman AM, Roye DG, Charpentier KP. A comparison of outcomes between open, laparoscopic and robotic pancreaticoduodenectomy. HPB (Oxford) 2018;20:364-9.

26. Mirkin KA, Greenleaf EK, Hollenbeak CS, et al. Time to the initiation of adjuvant chemotherapy does not impact survival in patients with resected pancreatic cancer. Cancer 2016;122:2979-87.

27. Nassour I, Wang SC, Porembka MR, et al. Robotic Versus Laparoscopic Pancreaticoduodenectomy: a NSQIP Analysis. J Gastrointest Surg 2017;21:1784-92.

28. Nassour I, Choti MA, Porembka MR, et al. Robotic-assisted versus laparoscopic pancreaticoduodenectomy:

oncological outcomes. Surg Endosc 2018;32:2907-13.

29. Zureikat AH, Breaux JA, Steel JL, et al. Can laparoscopic pancreaticoduodenectomy be safely implemented? J Gastrointest Surg 2011;15:1151-7.

30. Boone BA, Zenati M, Hogg ME, et al. Assessment of quality outcomes for robotic pancreaticoduodenectomy: identification of the learning curve. JAMA Surg 2015;150:416-22.

31. Napoli N, Kauffmann EF, Palmeri M, et al. The Learning Curve in Robotic Pancreaticoduodenectomy. Dig Surg 2016;33:299-307.

32. Speicher PJ, Nussbaum DP, White RR, et al. Defining the learning curve for team-based laparoscopic pancreaticoduodenectomy. Ann Surg Oncol 2014;21:4014-9.

33. Hogg ME, Besselink MG, Clavien PA, et al. Training in Minimally Invasive Pancreatic Resections: a paradigm shift away from "See one, Do one, Teach one". HPB (Oxford) 2017;19:234-45.

34. Birkmeyer JD, Finlayson SR, Tosteson AN, et al. Effect of hospital volume on in-hospital mortality with pancreaticoduodenectomy. Surgery 1999;125:250-6.

35. Ho V, Heslin MJ. Effect of hospital volume and experience on in-hospital mortality for pancreaticoduodenectomy. Ann Surg 2003;237:509-14.

36. Lieberman MD, Kilburn H, Lindsey M, et al. Relation of perioperative deaths to hospital volume among patients undergoing pancreatic resection for malignancy. Ann Surg 1995;222:638-45.

37. Sosa JA, Bowman HM, Gordon TA, et al. Importance of hospital volume in the overall management of pancreatic cancer. Ann Surg 1998;228:429-38.

38. Torphy RJ, Friedman C, Halpern A, et al. Comparing Short-term and Oncologic Outcomes of Minimally Invasive Versus Open Pancreaticoduodenectomy Across Low and High Volume Centers. Ann Surg 2018. [Epub ahead of print].

39. de Rooij T, van Hilst J, Topal B, et al. Outcomes of a Multicenter Training Program in Laparoscopic Pancreatoduodenectomy (LAELAPS-2). Ann Surg 2019;269:344-50.

40. Callery MP, Pratt WB, Kent TS, et al. A prospectively validated clinical risk score accurately predicts pancreatic fistula after pancreatoduodenectomy. J Am Coll Surg 2013;216:1-14.

41. Shubert CR, Wagie AE, Farnell MB, et al. Clinical Risk Score to Predict Pancreatic Fistula after Pancreatoduodenectomy: Independent External Validation

for Open and Laparoscopic Approaches. J Am Coll Surg 2015;221:689-98.

42. Chapman BC, Gajdos C, Hosokawa P, et al. Comparison of laparoscopic to open pancreaticoduodenectomy in elderly patients with pancreatic adenocarcinoma. Surg Endosc 2018;32:2239-48.

43. Kendrick ML, Sclabas GM. Major venous resection during total laparoscopic pancreaticoduodenectomy. HPB (Oxford) 2011;13:454-8.

44. Allan BJ, Novak SM, Hogg ME, et al. Robotic vascular resections during Whipple procedure. J Vis Surg 2018;4:13.

45. Kendrick ML, van Hilst J, Boggi U, et al. Minimally invasive pancreatoduodenectomy. HPB (Oxford) 2017;19:215-24.

46. Gerber MH, Delitto D, Crippen CJ, et al. Analysis of the Cost Effectiveness of Laparoscopic Pancreatoduodenectomy. J Gastrointest Surg 2017;21:1404-10.

47. Mesleh MG, Stauffer JA, Bowers SP, et al. Cost analysis of open and laparoscopic pancreaticoduodenectomy: a single institution comparison. Surg Endosc 2013;27:4518-23.

48. Tran TB, Dua MM, Worhunsky DJ, et al. The First Decade of Laparoscopic Pancreaticoduodenectomy in the United States: Costs and Outcomes Using the Nationwide Inpatient Sample. Surg Endosc 2016;30:1778-83.